Diazepam Stats & Data
Interaction Warnings
This combination can result in an increased risk of vomiting during unconsciousness and death from the resulting suffocation. If this occurs, users should attempt to fall asleep in the recovery position or have a friend move them into it.
It is dangerous to combine benzodiazepines with stimulants due to the risk of excessive intoxication. Stimulants decrease the sedative effect of benzodiazepines, which is the main factor most people consider when determining their level of intoxication. Once the stimulant wears off, the effects of benzodiazepines will be significantly increased, leading to intensified disinhibition as well as other effects.
Pharmacology
DrugBankDescription
A benzodiazepine with anticonvulsant, anxiolytic, sedative, muscle relaxant, and amnesic properties and a long duration of action. Its actions are mediated by enhancement of gamma-aminobutyric acid activity. It is used in the treatment of severe anxiety disorders, as a hypnotic in the short-term management of insomnia, as a sedative and premedicant, as an anticonvulsant, and in the management of alcohol withdrawal syndrome. (From Martindale, The Extra Pharmacopoeia, 30th ed, p589) Given diazepam's storied history as a commonly used and effective medication for a variety of indications, contemporary advancements in the formulation and administration of the agent include the development and US FDA approval of an auto-injectable formulation for the rapid treatment of uncontrolled seizures in 2015-2016 . Combining diazepam, a proven effective therapy for acute repetitive seizures, with an auto-injector designed for subcutaneous administration that is quickly and easily administered offers the potential for complete, consistent drug absorption and rapid onset of effect . This current development is subsequently an important addition to the rescue therapy tool chest for patients with epilepsy .
Mechanism of Action
Diazepam is a benzodiazepine tranquilliser with anticonvulsant, sedative, muscle relaxant and amnesic properties . Benzodiazepines, such as diazepam, bind to receptors in various regions of the brain and spinal cord. This binding increases the inhibitory effects of gamma-aminobutyric acid (GABA) . GABAs functions include CNS involvement in sleep induction. Also involved in the control of hypnosis, memory, anxiety, epilepsy and neuronal excitability .
Pharmacodynamics
Diazepam is a benzodiazepine that exerts anxiolytic, sedative, muscle- relaxant, anticonvulsant and amnestic effects . Most of these effects are thought to result from facilitation of the action of gamma aminobutyric acid (GABA), an inhibitory neurotransmitter in the central nervous system .
Metabolism
Diazepam is N-demethylated by CYP3A4 and 2C19 to the active metabolite N-desmethyldiazepam, and is hydroxylated by CYP3A4 to the active metabolite temazepam . N-desmethyldiazepam and temazepam are both further metabolized to oxazepam . Temazepam and oxazepam are further largely eliminated by way of conjugation to glucuronic acid via glucuronidation . Furthermore, oxidation of diazepam is mediated by cytochrome P450 isozymes; formation of desmethyl-diazepam mainly by CYP2C19 and CYP3A and 3-hydroxy-diazepam (temazepam) and oxazepam by CYP3A. Because CYP2C19 is polymorphic, extensive metabolizers (EMs), and poor metabolizers (PMs) of diazepam can be distinguished . PMs of diazepam showed significantly lower clearance (12 vs 26 mL/min) and longer elimination half-life (88 vs 41 h) of diazepam than EMs after a single oral dose . Also, PMs had lower clearance, higher AUC and longer elimination half-life of desmethyl-diazepam .
Absorption
After oral administration, it is considered that diazepam is rapidly and completely absorbed from the gastrointestinal tract as >90% of diazepam is absorbed and the average time to achieve peak plasma concentrations is 1 – 1.5 hours with a range of 0.25 to 2.5 hours . Absorption is delayed and decreased when administered with a moderate fat meal . In the presence of food mean lag times are approximately 45 minutes as compared with 15 minutes when fasting . There is also an increase in the average time to achieve peak concentrations to about 2.5 hours in the presence of food as compared with 1.25 hours when fasting . This results in an average decrease in Cmax of 20% in addition to a 27% decrease in AUC (range 15% to 50%) when administered with food .
Toxicity
The symptoms of diazepam overdose are mainly an intensification of the therapeutic effects (ataxia, drowsiness, dysarthria, sedation, muscle weakness, profound sleep, hypotension, bradycardia, nystagmus) or paradoxical excitation . In most cases only observation of vital functions is required . Extreme overdosage may lead to coma, areflexia, cardio-respiratory depression and apnoea, requiring appropriate countermeasures (ventilation, cardiovascular support) . Benzodiazepine respiratory depressant effects are more serious in patients with severe chronic obstructive airways disease . Severe effects in overdose also include rhabdomyolysis and hypothermia . Overdose of benzodiazepines in combination with other CNS depressants (including alcohol) may be fatal and should be closely monitored . In general, the use of diazepam in women of childbearing potential, and more specifically during known pregnancy, should be considered only when the clinical situation warrants the risk to the fetus . The possibility that a woman of childbearing potential may be pregnant at the time of institution of therapy should be considered . If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to the fetus .
Indication
In general, diazepam is useful in the symptomatic management of mild to moderate degrees of anxiety in conditions dominated by tension, excitation, agitation, fear, or aggressiveness such as may occur in psychoneurosis, anxiety reactions due to stress conditions, and anxiety states with somatic expression. Moreover, in acute alcoholic withdrawal, diazepam may be useful in the symptomatic relief of acute agitation, tremor, and impending acute delirium tremens. Furthermore, diazepam is a useful adjunct for the relief of skeletal muscle spasm due to reflex spasm to local pathologies, such as inflammation of the muscle and joints or secondary to trauma; spasticity caused by upper motor neuron disorders, such as cerebral palsy and paraplegia; athetosis and the rare "stiff man syndrome". Particular label information from the United Kingdom also lists particular age-specific indications, including for adults: (1) The short-term relief (2-4 weeks) only, of anxiety which is severe, disabling, or subjecting the individual to unacceptable distress, occurring alone or in association with insomnia or short-term psychosomatic, organic or psychotic illness, (2) cerebral palsy, (3) muscle spasm, (4) as an adjunct to certain types of epilepsy (eg. myoclonus), (5) symptomatic treatment of acute alcohol withdrawal, (6) as oral premedication for the nervous dental patient, and (7) for premedication before surgery.
Half-life
Diazepam has a biphasic half-life with an initial rapid distribution phase followed by a prolonged terminal elimination phase of 1 or 2 days; its action is further prolonged by the even longer half-life of 2-5 days of its principal active metabolite, desmethyldiazepam (nordiazepam), the relative proportion of which increases in the body on long-term administration . The plasma half-life of diazepam is prolonged in neonates, in the elderly, and in patients with kidney or liver disease .
Protein Binding
Despite high binding to plasma proteins (98-99%) - mainly albumin and to a lesser extent α1-acid glycoprotein - diazepam is widely distributed into tissues and crosses the blood-brain barrier and is highly lipid soluble, which causes the initial effects to decrease rapidly as it is redistributed into fat deposits and tissues .
Elimination
Diazepam and its metabolites are excreted mainly in the urine, predominantly as their glucuronide conjugates .
Volume of Distribution
In young healthy males, the volume of distribution at steady-state is 0.8 to 1.0 L/kg .
Clearance
The clearance of diazepam is 20 to 30 mL/min in young adults .
Receptor Profile
Receptor Actions
Receptor Binding
History & Culture
1959–1963
Diazepam was the second benzodiazepine developed by chemist Leo Sternbach at Hoffmann-La Roche's facility in Nutley, New Jersey, following his earlier creation of chlordiazepoxide (marketed as Librium), which had received approval for medical use in 1960. Sternbach patented diazepam in 1959, and it was released to market in 1963 as an improved formulation of its predecessor. The new compound demonstrated approximately 2.5 times greater potency than chlordiazepoxide, which it rapidly surpassed in commercial sales.
1963–1985
Following its 1963 launch, diazepam quickly became one of the most frequently prescribed medications in the world, a distinction it has maintained for decades. The drug's commercial success was propelled by an extensive marketing campaign conceived by the William Douglas McAdams Agency under the direction of Arthur Sackler. This promotional effort helped establish diazepam as the top-selling pharmaceutical in the United States from 1969 to 1982, with peak annual sales reaching 2.3 billion tablets in 1978 alone. The drug's commercial dominance transformed Hoffmann-La Roche into a pharmaceutical industry giant. When the patent expired in 1985, generic manufacturers entered the market, and diazepam has since been marketed under hundreds of brand names—currently exceeding 500 different formulations worldwide. Despite increased competition and evolving prescribing practices, the medication remains widely used; as of 2023, it ranked as the 183rd most commonly prescribed medication in the United States with more than 2 million prescriptions annually.
Beyond its conventional medical applications, diazepam has been adopted for several specialized institutional purposes. The United States military employs a specialized preparation known as CANA (Convulsive Antidote, Nerve Agent), which is typically issued to service members alongside Mark I NAAK kits when operating in environments where exposure to chemical weapons in the form of nerve agents is considered a potential hazard. Diazepam has also been incorporated into capital punishment protocols in the United States. The states of California and Florida offer the drug to condemned inmates as a pre-execution sedative within their lethal injection programs. In August 2018, Nebraska utilized diazepam as part of the drug combination administered during the execution of Carey Dean Moore, marking the first execution carried out in that state in over 21 years. In 2015-2016, the U.S. Food and Drug Administration approved an auto-injectable formulation of diazepam designed for the rapid treatment of uncontrolled seizures, representing a contemporary advancement in the drug's delivery methods.
Subjective Effect Notes
physical: The physical effects of diazepam can be broken down into several components which progressively intensify proportional to dosage.
cognitive: The cognitive effects of diazepam can be broken down into several components which progressively intensify proportional to dosage. The general head space of diazepam is described by many as one of intense sedation and decreased inhibition. It contains a large number of typical depressant cognitive effects. Paradoxical reactions to benzodiazepines such as increased seizures (in epileptics), aggression, increased anxiety, violent behavior, loss of impulse control, irritability and suicidal behavior sometimes occur (although they are rare in the general population, with an incidence rate below 1%). These paradoxical effects occur with greater frequency in recreational abusers, individuals with mental disorders, children, and patients on high-dosage regimes.
Effect Profile
Curated + 116 ReportsStrong anxiolysis with moderate sedation and cognitive impairment, low euphoria
User Experiences
Tolerance & Pharmacokinetics
drugs.wikiTolerance Decay
Tolerance develops to sedative/anxiolytic effects with repeated daily use over weeks and only slowly decays after cessation. Cross-tolerance is substantial across benzodiazepines and partial with other GABAergic sedatives.
Cross-Tolerances
Demographics
Gender Distribution
Age Distribution
Reports Over Time
Effect Analysis
Erowid + BluelightEffects aggregated from 116 experience reports (101 Erowid + 15 Bluelight)
Effect Sentiment Distribution
Confidence Distribution
Positive Effects 27
Adverse Effects 34
Dose-Response Correlation
How effect frequency changes across dose levels
View data table
| Effect | Common (n=25) | Strong (n=13) | Heavy (n=10) |
|---|---|---|---|
| Stimulation | 40.0% | 23.1% | 60.0% |
| Anxiety Suppression | 52.0% | 23.1% | 50.0% |
| Sedation | 52.0% | 38.5% | 50.0% |
| Euphoria | 32.0% | 38.5% | 50.0% |
| Tactile Enhancement | 28.0% | 0% | 40.0% |
| Confusion | 24.0% | 0% | 40.0% |
| Music Enhancement | 24.0% | 0% | 40.0% |
| Empathy | 20.0% | 23.1% | 40.0% |
| Focus Enhancement | 20.0% | 0% | 40.0% |
| Visual Distortions | 28.0% | 15.4% | 30.0% |
| Hospital | 8.0% | 15.4% | 30.0% |
| Sweating | 0% | 0% | 30.0% |
| Closed-Eye Visuals | 0% | 0% | 30.0% |
| Motor Impairment | 0% | 0% | 30.0% |
| Body High | 24.0% | 0% | 0% |
Dose–Effect Mapping
Experience ReportsHow reported effects shift across dose tiers, based on 101 experience reports.
| Effect | Common (n=25) | Strong (n=13) | Heavy (n=10) | |
|---|---|---|---|---|
| stimulation | ↑ | |||
| anxiety suppression | → | |||
| sedation | → | |||
| euphoria | ↑ | |||
| tactile enhancement | — | ↑ | ||
| confusion | — | ↑ | ||
| music enhancement | — | ↑ | ||
| empathy | ↑ | |||
| focus enhancement | — | ↑ | ||
| visual distortions | → | |||
| hospital | ↑ | |||
| sweating | — | — | → | |
| closed-eye visuals | — | — | → | |
| motor impairment | — | — | → | |
| body high | — | — | → | |
| pain relief | — | — | → | |
| seizure | — | — | → | |
| pupil dilation | — | — | → | |
| nausea | — | — | → | |
| muscle tension | — | — | → |
Showing top 20 of 24 effects
Risk Escalation
Sentiment AnalysisAverage frequency of positive vs adverse effects across dose tiers
View effect breakdown
Adverse Effects
| Effect | Common (n=25) | Strong (n=13) | Heavy (n=10) | Change |
|---|---|---|---|---|
| Anxiety Suppression | -3% | |||
| Confusion | — | +66% | ||
| Sweating | — | — | 0% | |
| Motor Impairment | — | — | 0% | |
| Seizure | — | — | 0% | |
| Pupil Dilation | — | — | 0% | |
| Nausea | — | — | 0% | |
| Muscle Tension | — | — | 0% | |
| Memory Suppression | — | +92% |
Positive Effects
| Effect | Common (n=25) | Strong (n=13) | Heavy (n=10) | Change |
|---|---|---|---|---|
| Stimulation | +50% | |||
| Euphoria | +56% | |||
| Tactile Enhancement | — | +42% | ||
| Music Enhancement | — | +66% | ||
| Empathy | +100% | |||
| Focus Enhancement | — | +100% | ||
| Body High | — | — | 0% | |
| Pain Relief | — | — | 0% | |
| Color Enhancement | — | — | 0% |
Dosage Distribution
Dose distribution from experience reports
Real-World Dose Distribution
62K DosesFrom 256 individual dose entries
Oral (n=205)
Insufflated (n=8)
Common Combinations
Most co-occurring substances in experience reports
Form / Preparation
Most common forms and preparations reported
Body-Weight Dosing
Dose relative to body weight from reports with weight data
Redose Patterns
Redosing behavior across 75 reports
Benzodiazepine Equivalence
Diazepam - 10mg ~=10mg Diazepam.
Legal Status
| Country | Status | Notes |
|---|---|---|
| Canada | Prescription | Approved prescription medication with various formulations marketed including oral tablets in multiple strengths and rectal gel preparations. |
| Indonesia | Prescription | Available as a prescription medication. Marketed both as a standalone product and in combination formulations with other active ingredients such as metamizole sodium. |
| United Kingdom | Prescription Only | Available exclusively through medical prescription. First launched in 1963 and has been one of the most widely prescribed medicines. Since its patent expired in 1985, it has been marketed under numerous brand names. |
| United States | Prescription (Controlled) | Classified as both 'Approved' and 'Illicit' indicating legitimate medical use alongside controlled substance status. Multiple prescription formulations are marketed including oral tablets, rectal gels (Diastat), and injectable solutions for intramuscular and intravenous administration. |
Harm Reduction
drugs.wikiDiazepam is long-acting and lipophilic; repeated or high doses can accumulate in fat with slow redistribution, causing prolonged next-day sedation and impaired coordination—avoid redosing to chase euphoria. Benzodiazepines plus opioids or alcohol markedly increase risk of respiratory depression, coma, and death; this combination carries an FDA boxed warning and should be strictly avoided. In older adults, paradoxical agitation, disinhibition, confusion, and falls are more likely; use the lowest possible dose or avoid non-prescribed use in this group. Hepatic impairment (cirrhosis, hepatitis) extends diazepam half-life substantially; even usual doses can over-sedate—avoid self-escalation and seek medical guidance. Diazepam is metabolized mainly by CYP2C19 and CYP3A4; strong inhibitors (e.g., ketoconazole, macrolides, protease inhibitors; some SSRIs and PPIs) can raise levels and increase sedation, while inducers (carbamazepine, phenytoin, rifampin, St John’s wort) can reduce effect unpredictably. Grapefruit products inhibit intestinal CYP3A4 and can raise exposure to several benzodiazepines; effect on diazepam may be smaller due to CYP2C19 involvement, but increased sedation is still possible—avoid co-use. Avoid driving, cycling, operating machinery, or risky activities for at least the day of use and until you feel fully alert the next day. Do not inject tablets or non-sterile solutions; IV diazepam requires medical-grade formulation and slow administration due to risks of apnea, hypotension, and solvent-related toxicity. Rectal and intranasal medical products exist for seizures but are not appropriate for recreational use. Abrupt cessation after days-to-weeks of regular use can cause severe withdrawal (anxiety, tremor, perceptual changes) and, at higher dependence levels, seizures; cessation should be gradual under medical supervision. Flumazenil can reverse benzodiazepine sedation but may precipitate withdrawal and seizures in dependent users; it is not a general safety net for non-medical use. Pregnancy and breastfeeding: diazepam crosses the placenta and enters breast milk; prenatal exposure is linked to neonatal withdrawal and floppy infant syndrome, and infants may become excessively sedated—avoid non-prescribed use and seek medical advice. Unregulated drug supplies can contain unexpected benzodiazepines or be co-formulated with opioids or veterinary tranquilizers; when available, use drug checking services and avoid unknown tablets.
References
Data Sources
Cited References
Drugs.wiki References
- StatPearls: Diazepam
- TripSit Wiki: Diazepam
- TripSit: Drug Combinations Chart
- DrugBank: Diazepam (DB00829)
- Erowid: Diazepam Vault
- EUDA: Misuse of benzodiazepines among high-risk opioid users
- DrugBank Article: Grapefruit juice interaction with benzodiazepines (triazolam/quazepam)
- Drug Checking Community: Benzo-dope overview
- StatPearls: Omeprazole (CYP2C19 inhibition affecting diazepam)
- Ashton Manual (archived on Drugs-Forum): Equivalence and withdrawal risks